Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.1249 |
---|---|
High | 0.1316 |
Low | 0.1249 |
Bid | 0.1282 |
Offer | 0.1339 |
Previous close | 0.1524 |
Average volume | 31.60k |
---|---|
Shares outstanding | 193.18m |
Free float | 180.87m |
P/E (TTM) | -- |
Market cap | 25.85m USD |
EPS (TTM) | -0.2443 USD |
Data delayed at least 15 minutes, as of Nov 25 2024 09:18 GMT.
More ▼
- Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split
- Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering
- Citius Pharmaceuticals Announces $3 Million Registered Direct Offering
- Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors
- Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
- Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology
More ▼